Table 5.
Comparison of metabolic disease outcomes 2 years after between the two groups
| SG | SADI-S | p | |
|---|---|---|---|
| 12mo FBG(mmol/L) | 5.9(5.3–6.8)a | 5.4(4.9–5.9) | 0.022* |
| 12mo HbA1c (%) | 6(5.6–6.7) | 5.2(4.9–5.6) | 0.000* |
| 12mo T2DM CR | 15(51.7%) b | 22(91.7%) | 0.000* |
| 24mo FBG(mmol/L) | 5.8(5.1–7.3) | 5.2(4.9–5.6) | 0.020* |
| 24mo HbA1c (%) | 6.2(5.7–6.6) | 5.1(4.9–5.6) | 0.000* |
| 24mo T2DM CR | 12(41.4%) | 22(91.8%) | 0.000* |
| 12mo SBP(mmHg) | 120.2 ± 13c | 121.3 ± 14 | 0.763 |
| 12mo DBP(mmHg) | 72.5 ± 8.1 | 76.1 ± 9.3 | 0.132 |
| 12mo Hypertension CR | 15(88%) | 12(83.3%) | 1.000 |
| 24mo SBP(mmHg) | 119.9 ± 9 | 117.5 ± 10.8 | 0.380 |
| 24mo DBP(mmHg) | 74.2 ± 7.5 | 74.1 ± 7.8 | 0.982 |
| 24mo Hypertension CR | 16(94.1%) | 12(100%) | 1.000 |
| 12mo TG(mmol/L) | 1.1(0.9–1.4) | 1.2(0.9–1.3) | 0.789 |
| 12mo TC(mmol/L) | 5.1 ± 1.2 | 3.8 ± 0.7 | 0.000* |
| 12mo hyperlipidemia CR | 10 (45.5%) | 14 (93.3%) | 0.003* |
| 24mo TG(mmol/L) | 1.2(0.8–1.4) | 1.1(0.9–1.2) | 0.228 |
| 24mo TC(mmol/L) | 5.1 ± 1.1 | 4.1 ± 0.6 | 0.000* |
| 24mo hyperlipidemia CR | 11 (50%) | 13(86.7%) | 0.022* |
SG Sleeve gastrectomy, SADI-S Single-anastomosis duodenal-ileal bypass with sleeve gastrectomy, FPG Fasting plasma glucose, HbA1c Glycated hemoglobin, T2DM CR Type 2 diabetes mellitus complete remission, SBP Systolic blood pressure, DBP Diastolic blood pressure, TC Total cholesterol, TG Triglyceride
p* < 0.05 was considered statistically significant
a Median (ranges)
b Number of patients (percentage of patients)
c Mean ± standard deviation